Condition: Arthroplasty, Replacement, Knee · Nerve Block Assessment · Pain, Postoperative Arthroscopy · Sponsor: Konya City Hospital
Total knee arthroplasty (TKA) is associated with substantial postoperative pain and opioid requirements, making effective multimodal analgesia essential for early mobilization, functional recovery, and reduction of opioid-related adverse events \[1,2\]. Adductor canal block (ACB) has become a key component of enhanced recovery after surgery (ERAS) protocols because it provides effective anterior knee analgesia while largely preserving quadriceps muscle strength \[2-4\]. However, analgesic efficacy after ACB remains variable, and some patients require rescue opioid analgesia despite technically successful block placement \[5\]. Although ultrasound guidance improves block accuracy, factors such as tissue depth, anatomical variations, saphenous nerve visibility, and injectate spread pattern may influence clinical outcomes \[6,7\]. Prospective evidence regarding the predictive value of these ultrasound-derived parameters for ACB analgesic failure remains limited. Therefore, this study aims to evaluate whether preoperative ultrasound-derived tissue and target parameters-including skin-to-target depth, subcutaneous fat thickness, muscle thickness, saphenous nerve visibility, and injectate spread pattern-can predict ACB analgesic failure and early postoperative analgesic outcomes following TKA.
This description comes directly from the study's public registry record.
Ömer Keklicek, Principal Investigator · +905399291702 · drokeklicek@gmail.com
Always discuss trial participation with your own doctor first.
| Konya City Hospital | Konya, Konya, Turkey (Türkiye) | — |
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.